Portfolio Companies News
May 18, 2022BONESUPPORT receives market authori...
Published: 2022-05-18 BONESUPPORT ™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has received market authorization from the US Food and Drug Administration (FDA), for the company's antibiotic eluting product CERAMENT G, for the ind... read more
May 16, 2022Aprea Therapeutics Announces Acquis...
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceu... read more
May 12, 2022Xeris Announces Full Results From t...
CHICAGO--(BUSINESS WIRE)--May 12, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced it is presenting new data on the b... read more
May 12, 2022Targovax ASA: First quarter 2022 re...
Oslo, Norway, 12 May 2022 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2022 results. Members of Targovax’s executive management team will give an online presentation t... read more
May 11, 2022Spruce Biosciences Reports First Qu...
25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Million Credit Line in 2022 Tildacerfont Patent Portfolio Estate Expanded with Key Method of ... read more
May 16, 2022Q1 2022 General Market Overview
October 07, 2021HealthCap strengthens senior team
November 29, 2021HealthCap’s 25th company anniversary!
Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.
46 of the portfolio companies have been taken public on fourteen different markets.
30 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.